Pharma Focus Asia

Astellas Completes Acquisition of Ogeda SA

Wednesday, May 17, 2017

Astellas Pharma Inc. announced that it has completed the acquisition of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of Astellas as of CET May 17, 2017.

Under the share purchase agreement executed between Astellas and Ogeda shareholders, Astellas paid EUR 500 million to acquire 100% of the equity in Ogeda. In addition, Ogeda shareholders will become eligible to receive up to EUR 300 million in further contingent payments based on progress in the development of fezolinetant, Ogeda's most advanced clinical program for the treatment of menopausal-related vasomotor symptoms.

This transaction expands Astellas' late stage pipeline and is expected to contribute to its mid-to-long term growth.

Astellas reflected the impact from this closing of transaction in its financial forecasts of the current fiscal year ending March 31, 2018

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024